[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346421-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346421-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","integrating-virtual-screening-and-molecular-dynamics-simulations-to-identify-emodin-as-a-pycr1-inhibitor-modulating-docetaxel-sensitivity-in-prostate-cancer","Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer","","Docetaxel (DTX) resistance drives treatment failure in castration-resistant prostate cancer. Pyrroline-5-carboxylic acid reductase 1 (PYCR1), a proline metabolism-related enzyme, is highly expressed in cancers, but its contribution to DTX resistance in prostate cancer remains unclear. Bioinformatics and in vitro/in vivo experiments show that suppressing PYCR1 alters DTX sensitivity. Structure-based virtual screening, molecular dynamics simulations, and cellular thermal shift assay identify emodin as a PYCR1-targeting agent, and emodin–DTX displays potential to overcome resistance. In vitro testing also supports functions and safety.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/integrating-virtual-screening-and-molecular-dynamics-simulations-to-identify-emodin-as-a-pycr1-inhibitor-modulating-docetaxel-sensitivity-in-prostate-cancer/346421/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/integrating-virtual-screening-and-molecular-dynamics-simulations-to-identify-emodin-as-a-pycr1-inhibitor-modulating-docetaxel-sensitivity-in-prostate-cancer/346421.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is docetaxel resistance a major problem in castration-resistant prostate cancer?","Question",{"text":63,"@type":64},"Docetaxel resistance is identified as the main cause of treatment failure in castration-resistant prostate cancer, leading to reduced clinical efficacy and disease recurrence after initial response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does PYCR1 play according to the study?",{"text":68,"@type":64},"PYCR1 is described as an enzyme involved in proline metabolism that is highly expressed in cancers and may mediate docetaxel resistance in prostate cancer. Interfering with PYCR1 expression is reported to modulate prostate cancer cell sensitivity to docetaxel.",{"name":70,"@type":61,"acceptedAnswer":71},"How was emodin identified as a PYCR1-related agent?",{"text":72,"@type":64},"Emodin was identified through structure-based virtual screening and supported by molecular dynamics simulations and a cellular thermal shift assay, indicating it targets PYCR1. The study further links the emodin–docetaxel combination to overcoming resistance potential, with in vitro verification of functions and safety.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346421,1790785077,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":99,"preview_page_count":33,"preview_urls":145},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Journal of EnzymE InhIbItIon and mEdIcInal chEmIstry 2026, Vol. 41, no. 1, 2622725  \n[https://doi.org/10.1080/14756366.2026.2622725](https://doi.org/10.1080/14756366.2026.2622725)  \nReseaRch aRticle    \nIntegrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer  \nshuai liua\\#, Yongfeng laoa\\#, long chenga, Xi Xiaoa, longtu Maa, Wenyun Wangb, Kun Zhaoa, Wenxuan lia, Zhongze Zhoua, Qingchao lib, Yan taoc, shanhui liuc and Zhilong Dongb  \nadepartment of urology, the second hospital and clinical medical school, lanzhou university, lanzhou, Gansu, china; bdepartment of urology, Gansu Province clinical research center for urinary system disease, the second hospital and clinical medical school, lanzhou university, lanzhou, Gansu, china; cInstitute of urology, Gansu Province clinical research center for urinary system disease, the second hospital and clinical medical school, lanzhou university, lanzhou, Gansu, china  \nABSTRACT  \nDocetaxel (DtX) resistance is the main cause of treatment failure in castration-resistant prostate cancer (cRPc). Pyrroline-5-carboxylic acid reductase 1 (PYcR1) is an enzyme involved in [proline metabolism. it](proline metabolism. it) is highly expressed in various cancers and promotes malignant progression, yet its role in DtX resistance in prostate cancer remains unclear. in this study, bioinformatics analyses and in vitro/vivo experiments demonstrated that interfering with PYcR1 expression modulates the sensitivity of prostate cancer cells to DtX. subsequently, via structure-based virtual screening, molecular dynamics simulations, and cellular thermal shift assay (cetsa), emodin—an anthraquinone compound—was identified as a PYcR1-targeting agent. collectively, these findings suggest that PYcR1 may serve as a key target mediating DtX resistance in prostate cancer, and the emodin–DtX combination provides a promising potential clinical strategy to overcome such resistance. Finally, its functions and safety were also verified through in vitro experiments.  \nIntroduction  \nARTICLE HISTORY  \nReceived 24 October 2025  \nRevised 19 January 2026 accepted 21 January 2026  \nKEYWORDS  \nDocetaxel; emodin; prostate cancer; PYcR1; virtual screening  \nProstate cancer (Pc) is among the most commonly diagnosed malignant neoplasms in men across the world, with its incidence showing a year-by-year increasing trend, especially among the ageing population1. according to the 2025 U.s. cancer statistics, prostate cancer has become the most common cancer in men by incidence2. in china, the initial diagnosis stage of prostate cancer patients is often delayed, and the chances of undergoing radical treatment are limited. approximately 70% of patients are already in the advanced metastatic stage at the time of their initial diagnosis. this results in a 5-year survival rate of only 67%, which is significantly lower than the 96.7% found in developed countries such as those in europe and america3–5. therefore, the prevention and treatment situation of prostate cancer in china  \nis particularly serious, and it has become one of the important public health issues in our country.  \nin the advanced stage, patients usually develop castration-resistant prostate cancer (cRPc) . at this point, DtX is used as the first-line chemotherapy drug6. By inhibiting microtubule depolymerisation and blocking the cell cycle, it becomes an important treatment option7,8. DtX chemotherapy is usually effective in initially inhibiting tumour progression and improving patient survival. however, the emergence of  \nCONTACT zhilong dong [dzl19780829@163.com](dzl19780829@163.com) department of urology, Gansu Province clinical research center for urinary system disease, the second hospital and clinical medical school, lanzhou university, lanzhou, 730030, Gansu, china; shanhui liu  ery_liushery@ [lzu.edu.cn](lzu.edu.cn)  Institute of urology, Gansu Province clinical researc","cbCaiiylyxATCNRj","https://ap.wps.com/l/cbCaiiylyxATCNRj","pdf",4108458,24,"English","# Abstract\n# Introduction\n## Docetaxel resistance in castration-resistant prostate cancer\n## PYCR1 and prostate cancer metabolism\n## Study rationale and approach\n# Article Information\n## Received/Revised/Accepted\n## Keywords","[{\"question\":\"Why is docetaxel resistance a major problem in castration-resistant prostate cancer?\",\"answer\":\"Docetaxel resistance is identified as the main cause of treatment failure in castration-resistant prostate cancer, leading to reduced clinical efficacy and disease recurrence after initial response.\"},{\"question\":\"What role does PYCR1 play according to the study?\",\"answer\":\"PYCR1 is described as an enzyme involved in proline metabolism that is highly expressed in cancers and may mediate docetaxel resistance in prostate cancer. Interfering with PYCR1 expression is reported to modulate prostate cancer cell sensitivity to docetaxel.\"},{\"question\":\"How was emodin identified as a PYCR1-related agent?\",\"answer\":\"Emodin was identified through structure-based virtual screening and supported by molecular dynamics simulations and a cellular thermal shift assay, indicating it targets PYCR1. The study further links the emodin–docetaxel combination to overcoming resistance potential, with in vitro verification of functions and safety.\"}]","Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer | PDF",1790061382,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08286fce3f7557edcbaf801d21a607e2.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfcfc1d51641a7086b293caf97e37e2e.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44a960f6ca4342d59cce6bb8f478c0c3.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd5cbaa5e9c99396dad062367279d3fb.webp",980,1306]